IGF-1 (Hair-Focused)
What the Research Actually Shows
Human: 2 studies, 5 groups · Animal: 2 · In Vitro: 1
The growth factor your dermal papilla cells depend on for every hair cycle—with textbook-level biology, a direct connection to finasteride's mechanism, and not a single controlled human trial for hair regrowth
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
IGF-1 is a growth factor your body makes naturally. Cells at the base of every hair follicle depend on IGF-1 to start and maintain each growth cycle. When those cells make less IGF-1—which happens in balding scalps—hairs miniaturize and eventually stop growing. People who respond to finasteride show increased IGF-1 in their follicles, which may explain part of why the drug works. Despite this strong biological case, no one has run a controlled study testing whether giving IGF-1 directly—by injection, serum, or any other method—regrows hair in humans. The compound is also a potent growth signal for many cell types, which raises real safety questions about long-term use.
IGF-1 (insulin-like growth factor 1) is a 70-amino-acid polypeptide produced throughout the body—primarily by the liver under growth hormone stimulation, but also locally by dermal papilla cells (DPCs) in hair follicles. In the context of hair biology, IGF-1 is not a minor player. It is the primary mitogenic signal that drives follicular keratinocytes into the growth phase, prevents premature apoptosis, and controls hair shaft differentiation. This is textbook-level biology, confirmed by knockout models, in vitro studies, and decades of characterization.
The clinical puzzle is that this understanding has never translated into an interventional trial. No study has applied exogenous IGF-1 to human scalps and measured hair counts. What exists instead is correlational evidence—case reports of alopecia patients with low systemic IGF-1 (Trüeb, 2017), the finasteride-IGF-1 mRNA connection (Inui et al., 2003), and epidemiological associations between serum IGF-1 levels and hair density in middle-aged women. These observations are consistent with the mechanism but do not prove that adding IGF-1 regrows hair.
This article examines IGF-1's established role in hair biology, explains why the translation gap exists, and assesses the practical obstacles—size, delivery, safety—that separate beautiful science from a proven therapy.
In This Article
Quick Facts: IGF-1 (Hair-Focused) at a Glance
Type
Endogenous polypeptide growth factor (single-chain, 70 amino acids)
Also Known As
Insulin-like Growth Factor 1, Somatomedin C, Mecasermin (pharmaceutical name)
Generic Name
IGF-1 (mecasermin for pharmaceutical-grade recombinant form)
Route
Systemic: subcutaneous injection (pharmaceutical—mecasermin). Topical: experimental serums (unvalidated delivery). No injectable protocol exists for hair specifically.
Molecular Weight
7,649 Da (too large for passive transdermal absorption)
Peptide Sequence
70-amino-acid single chain with three disulfide bonds; structural homology to proinsulin
Endogenous Origin
Yes. Circulating IGF-1 produced by liver under GH stimulation. Paracrine IGF-1 produced locally by dermal papilla cells in hair follicles.
Primary Molecular Function
Binds IGF-1R (tyrosine kinase receptor) → activates PI3K/Akt (anti-apoptosis, cell survival) and MAPK/ERK (proliferation) → drives anagen entry, sustains growth phase, controls shaft differentiation
Active Fragment
Full-length 70-amino-acid protein is the active form. Des(1-3) IGF-1 and IGF-1 LR3 are synthetic analogs with altered binding (covered in Cluster N—Performance)
Brand Name
Increlex (mecasermin)—FDA-approved for severe primary IGF-1 deficiency, NOT for hair loss or cosmetic use
Related Compound Relationship
IGF-1 LR3 and IGF-1 DES are in Cluster N (Performance). GH secretagogues (GHRP-6, Ipamorelin, MK-677 in Cluster D) raise circulating IGF-1 indirectly. This entry covers endogenous IGF-1 signaling in hair biology specifically.
Clinical Programs
Increlex approved for severe primary IGF-1 deficiency (growth disorders). Zero clinical trials registered for IGF-1 in hair loss—no IND, no Phase I, nothing.
Community Interest
Niche. Some vendors sell "IGF-1 scalp serums" for microneedling protocols, but IGF-1 for hair is not mainstream in the peptide community. Performance use (Cluster N) dominates community interest. Hair community focus is on GHK-Cu, Thymosin Beta-4 fragments, and finasteride.
FDA Status
Mecasermin approved for severe primary IGF-1 deficiency. NOT approved for hair loss, alopecia, or any cosmetic indication. No topical IGF-1 product is FDA-approved.
WADA Status
Prohibited at all times (S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics)
Half-Life
Circulating: ~12–15 hours (bound to IGFBP-3/ALS complex). Free IGF-1: ~10–12 minutes. Topical pharmacokinetics: unknown—no data.
Evidence Tier
3 Pilot / Limited Human Data
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is IGF-1?
Pronunciation: eye-jee-eff ONE
Every hair on your head exists in a cycle: growth, regression, rest, and shed. The signal that starts each growth phase comes from a tiny cluster of specialized cells at the base of the follicle called the dermal papilla. These cells are the command center. And the primary growth factor they send to the surrounding hair matrix cells—the molecule that says "divide, grow, build a hair shaft"—is IGF-1.
Insulin-like growth factor 1 is a 70-amino-acid polypeptide with three internal disulfide bonds and a structure that resembles proinsulin. The body makes it in two ways: the liver secretes IGF-1 into the bloodstream under growth hormone stimulation (the endocrine route), and individual tissues—including dermal papilla cells—produce it locally for their neighbors (the paracrine route). For hair biology, the paracrine IGF-1 from dermal papilla cells is what matters most.
When IGF-1 binds its receptor (IGF-1R, a tyrosine kinase receptor) on follicular keratinocytes, it activates two major pathways. PI3K/Akt prevents premature cell death, keeping the follicle in the growth phase longer. MAPK/ERK drives cell proliferation, pushing matrix cells to divide and build the hair shaft. Downstream, IGF-1 also upregulates PDGF and VEGF—growth factors that strengthen the follicular structure and improve blood supply to the follicle.
The pharmaceutical-grade recombinant form is called mecasermin (brand name Increlex), and it is FDA-approved—but only for children with severe primary IGF-1 deficiency, a rare growth disorder. It has never been studied, approved, or indicated for hair loss in any form.
PLAIN ENGLISH
IGF-1 is the main "grow" signal that the cells at the base of your hair follicle send to the cells that actually build each hair. Without enough IGF-1, follicles shrink and hair thins. It is not a cosmetic ingredient—it is a pharmaceutical-grade growth factor approved only for a rare growth disorder in children.
Origins and Discovery
IGF-1's discovery had nothing to do with hair. In 1957, salmon and Daughaday published their "somatomedin hypothesis"—the idea that growth hormone does not act directly on tissues but instead stimulates the liver to produce a secondary mediator that does the actual work. That mediator was eventually isolated, characterized, and named insulin-like growth factor 1 in 1978, reflecting its structural similarity to insulin and its potent mitogenic effects on cultured cells.
The hair connection emerged decades later. In the 1990s and early 2000s, researchers studying dermal papilla cell biology began identifying the specific growth factors that these cells secrete during anagen—the active growth phase. IGF-1 consistently emerged as the primary mitogenic factor. Liu et al. (2006, PMID 16778791) provided definitive proof using conditional IGF-1 receptor knockout mice: when follicular cells could not respond to IGF-1, hair growth was severely retarded and shaft differentiation was disrupted. The growth factor was not merely associated with hair growth—it was required for it.
The finasteride-IGF-1 connection—discovered by Inui et al. in 2003—was the clinical surprise. Patients who responded to finasteride showed increased IGF-1 mRNA in their dermal papilla cells. Non-responders did not. This suggested that finasteride, a drug designed to block DHT, was partially working by restoring IGF-1 signaling in the follicle. It reframed one of the most widely prescribed hair loss drugs through the lens of IGF-1 biology.
Yet despite this decades-long accumulation of mechanistic evidence, no one has ever tested exogenous IGF-1 for hair growth in a controlled human trial. The compound is simultaneously the best-understood growth factor in hair biology and one of the least clinically tested for that specific application.
Mechanism of Action
IGF-1 as the Dermal Papilla Master Signal
The dermal papilla (DP) is a cluster of specialized mesenchymal cells at the base of every hair follicle. These cells determine follicle size, cycle timing, and growth capacity. They do this primarily by secreting growth factors to the overlying hair matrix keratinocytes—the cells that actually divide to build the hair shaft. IGF-1 is the dominant mitogenic signal in this exchange.
When a follicle enters anagen (growth phase), DP cells upregulate IGF-1 production. The secreted IGF-1 binds to IGF-1R on matrix keratinocytes, initiating a signaling cascade through two parallel pathways:
PI3K/Akt pathway: IGF-1R activation phosphorylates PI3K, which activates Akt (protein kinase B). Akt phosphorylates pro-apoptotic proteins Bad and caspase-9, inactivating them. This prevents premature follicular apoptosis—the cellular death program that triggers catagen (regression). The net effect is longer anagen duration, meaning each hair grows for more months before cycling out.
MAPK/ERK pathway: Simultaneously, IGF-1R activates Ras/Raf/MEK/ERK, driving cell division in the matrix. This is the proliferative arm—more cell divisions means a thicker hair shaft built from more cells per unit length. ERK activation also upregulates cyclin D1 and other cell cycle regulators.
PLAIN ENGLISH
IGF-1 does two things in your hair follicle: it keeps hair-building cells alive longer (so each hair grows for more months before falling out) and it makes those cells divide faster (so each hair is thicker). Both effects work through the same receptor.
Downstream Amplification
IGF-1 does not act alone. Downstream of the initial IGF-1R signal:
PDGF-A and PDGF-B are upregulated (Ahn et al., 2012; PMID: PMC3283847), creating additional paracrine signals between DP cells and the follicular epithelium. VEGF is stimulated, promoting perifollicular angiogenesis—the growth of tiny blood vessels around the follicle that deliver oxygen and nutrients. Hair shaft differentiation—the organized layering of cortex, cuticle, and medulla—depends on IGF-1 signaling timing, as demonstrated by the disorganized shafts in IGF-1R knockout mice (Liu et al., 2006).
The IGF-1 Deficit in Androgenetic Alopecia
DPCs from balding scalp regions secrete significantly less IGF-1 than DPCs from non-balding regions of the same individual (PMID 24499417). This deficit correlates with follicular miniaturization—the progressive shrinking of follicles that characterizes androgenetic alopecia. The mechanism linking androgen exposure to IGF-1 suppression involves DHT-mediated repression of IGF-1 gene expression in DP cells, which is why 5-alpha reductase inhibitors (finasteride, dutasteride) can partially restore IGF-1 levels.
Patients with systemic IGF-1 deficiency—those with growth hormone insensitivity (Laron syndrome) or adult GH deficiency—exhibit thin, sparse, slow-growing hair that responds poorly to conventional treatments. This clinical correlation, while not proof of causation for cosmetic hair loss, demonstrates that IGF-1 signaling is necessary for normal hair maintenance.
PLAIN ENGLISH
In balding areas of the scalp, the cells that control hair growth make less IGF-1 than in non-balding areas. Finasteride works partly by restoring this IGF-1 production. People with medical conditions that cause low IGF-1 throughout the body have thin, sparse hair that does not respond well to standard treatments.
Key Research Findings
The Finasteride-IGF-1 Connection (Inui et al., 2003)
Inui and colleagues studied 9 men with androgenetic alopecia treated with finasteride for 48 weeks. Using microdissected DPCs from scalp biopsies before and after treatment, they measured IGF-1 mRNA expression. The finding: finasteride responders (patients with clinically visible regrowth) showed increased IGF-1 mRNA in their DPCs. Non-responders—patients who took finasteride but saw no improvement—showed no change in IGF-1 expression. This study did not test exogenous IGF-1 for hair growth, but it provided a direct clinical link between IGF-1 levels in the follicle and treatment response. It also suggested that finasteride may partially work by relieving DHT-mediated suppression of IGF-1 transcription (PMID 12894070).
Case Reports of IGF-1 Deficiency and Alopecia (Trüeb, 2017)
Trüeb described 3 alopecia patients with documented low serum IGF-1. All were treatment-resistant—they had failed multiple conventional therapies. While case reports cannot establish causation, they documented a pattern: when systemic IGF-1 is deficient, hair loss treatments do not work well. This is consistent with the mechanistic picture but does not prove that adding IGF-1 would reverse the resistance (PMID 29765966).
IGF-1 Drives Hair Growth in Mice (Ahn et al., 2012)
A controlled animal study in C57BL/6 mice demonstrated that topical recombinant IGF-1 promoted hair growth through anti-apoptotic effects (Akt activation) and PDGF upregulation. Treated areas showed earlier anagen entry and denser hair regrowth compared to vehicle controls. This is the closest thing to a proof-of-concept for exogenous IGF-1 as a hair growth treatment—but it was done in mice, and mouse hair biology differs significantly from human androgenetic alopecia (PMID: PMC3283847).
IGF-1R Knockout Confirms Essential Role (Liu et al., 2006)
Conditional knockout of IGF-1R in mouse follicles produced retarded hair growth, disorganized hair shaft structure, and aberrant hair cycle timing. This loss-of-function experiment confirmed that IGF-1 signaling is not merely correlated with hair growth—it is mechanistically required. Without functional IGF-1R, follicles cannot properly enter anagen, maintain proliferation, or differentiate the hair shaft (PMID 16778791).
Comprehensive Review of IGF-1 in Hair Biology (2025)
A 2025 review (PMID 41020895) synthesized decades of IGF-1 hair research and identified the compound as a central node in follicular signaling networks—connecting Wnt, BMP, and androgen pathways through DP cell biology. The review noted the "translational paradox": IGF-1's role is among the most well-characterized of any growth factor in hair biology, yet no clinical translation has been attempted for hair-specific indications.
Safety Profile
Systemic IGF-1 — Known Risks
The safety profile of systemic IGF-1 is well-characterized from the pharmaceutical use of mecasermin (Increlex) and from epidemiological studies of IGF-1 levels and disease risk:
Cancer risk: IGF-1 is mitogenic—it promotes cell division. Epidemiological studies consistently associate higher circulating IGF-1 levels with increased risk of prostate, breast, colorectal, and lung cancers. This is not a theoretical concern. Meta-analyses of prospective studies show statistically significant dose-response relationships between IGF-1 levels and cancer incidence. Exogenous IGF-1 administration would be expected to amplify this risk.
Metabolic effects: Hypoglycemia (IGF-1 binds insulin receptor at high concentrations), insulin resistance with chronic elevation, altered glucose homeostasis. These are dose-dependent and clinically significant.
Musculoskeletal: Arthralgia, jaw and extremity growth, increased intracranial pressure—documented adverse effects from mecasermin therapy in pediatric patients.
Cardiovascular: Left ventricular hypertrophy with chronic supraphysiological exposure.
Topical IGF-1 — Unknown
No published safety data exists for topical scalp application of IGF-1. The theoretical expectation—minimal systemic absorption of a 7,649 Da protein through intact skin—suggests low risk of systemic effects. However, this has never been tested, and microneedling protocols (which create temporary breaks in the skin barrier) could increase absorption unpredictably.
Local risks include theoretical hyperproliferation at the application site. IGF-1 stimulates division in keratinocytes, sebocytes, and other skin cells—not only follicular cells.
PLAIN ENGLISH
Systemic IGF-1 has real risks: it is a growth signal for all cells, not just hair cells, and higher blood levels are linked to higher cancer risk. Nobody knows whether putting it on your scalp is safe because nobody has studied it. The protein is large enough that it probably does not get absorbed through unbroken skin—but microneedling changes that equation, and no data exists.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “IGF-1 is the primary growth signal in hair follicles” | Knockout models, in vitro DPC studies, decades of mechanistic research | Supported |
| “Balding follicles have reduced IGF-1 signaling” | DPC secretion studies comparing balding vs. non-balding regions | Supported |
| “Finasteride works partly by restoring follicular IGF-1” | Clinical correlation in 9 AGA patients—responders showed increased IGF-1 mRNA | Mixed Evidence |
| “Topical IGF-1 promotes hair growth” | Mouse study (Ahn 2012) showed growth promotion; zero human data | Preclinical Only |
| “Low serum IGF-1 causes treatment-resistant alopecia” | 3 case reports—consistent but not controlled or powered | Mixed Evidence |
| “IGF-1 extends the growth phase of each hair cycle” | Mechanistic evidence strong (PI3K/Akt anti-apoptosis); no human duration data | Preclinical Only |
| “IGF-1 scalp serums promote hair regrowth” | No published data on topical scalp IGF-1 in humans. Delivery of a 7,649 Da protein through skin is pharmacologically questionable. | Unsupported |
| “Microneedling with IGF-1 improves hair density” | Theoretical only—no study combines microneedling with exogenous IGF-1 for hair | Theoretical |
| “IGF-1 is safer than minoxidil for hair growth” | No comparison exists. Systemic IGF-1 carries cancer risk and metabolic effects. Topical safety data: zero. | Unsupported |
| “GH secretagogues improve hair by raising IGF-1” | Plausible mechanism—MK-677 raises systemic IGF-1—but no study measures hair outcomes | Theoretical |
| “IGF-1 deficiency syndromes prove causation for AGA” | GH deficiency and Laron syndrome cause sparse hair, but AGA pathology is distinct (DHT-mediated, follicle-specific) | Mixed Evidence |
| “IGF-1 combined with PRP is the next generation hair treatment” | Speculative. PRP contains IGF-1 among many growth factors, but no controlled combination study isolates the contribution | Theoretical |
The Human Evidence Landscape
The honest summary of human evidence for IGF-1 in hair is brief and humbling for a compound with such extraordinary mechanistic credentials.
Two categories of human data exist, and neither constitutes a clinical trial:
Correlational evidence: Inui et al. (2003) showed that finasteride responders have higher DPC IGF-1 mRNA than non-responders. Middle-aged women with lower serum IGF-1 levels have higher prevalence of diffuse thinning. These observations are consistent with the biology but cannot establish that adding exogenous IGF-1 regrows hair.
Case reports: Trüeb (2017) described three alopecia patients with documented low systemic IGF-1 who were resistant to conventional treatments. A pattern—not proof.
What does not exist: any controlled trial—randomized or not, blinded or not, any sample size—testing topical, injectable, or any formulation of exogenous IGF-1 for hair regrowth in humans. The compound with the strongest mechanistic case in this cluster has the weakest clinical translation for hair specifically.
The reasons are not mysterious: IGF-1 is a potent mitogen for many cell types (cancer concern), it is a 7,649 Da protein (topical delivery barrier), and there is no commercial incentive—the compound is not patentable, and any clinical trial for a cosmetic hair indication would be expensive with uncertain regulatory pathway. The translation gap is structural, not scientific.
Legal and Regulatory Status
IGF-1's regulatory status is complex because the compound exists in two different contexts:
Pharmaceutical: Mecasermin (Increlex) is an FDA-approved biologic for severe primary IGF-1 deficiency in children. It is a prescription-only injectable. Using mecasermin off-label for hair loss would be legal in the US (off-label prescribing is permitted) but no physician guidelines or evidence base supports this, and the risk-benefit ratio would be unfavorable for a cosmetic indication.
Research/cosmeceutical: Some vendors sell "IGF-1 scalp serums" as cosmetic products. These occupy a regulatory gray zone—they are not making drug claims, but the inclusion of a recombinant growth factor in a topical product raises questions about proper classification under FDA cosmetic regulations (21 CFR Part 700 vs. drug classification if therapeutic claims are made).
WADA: IGF-1 is prohibited at all times under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Any athlete using IGF-1 in any form—including topical scalp serums—risks a doping violation.
Research Protocols
Published research protocols involving IGF-1 and hair:
Inui et al. (2003): Oral finasteride 1 mg/day for 48 weeks. Scalp biopsies before and after treatment. DPC microdissection and RT-PCR for IGF-1 mRNA quantification. Clinical response assessed by global photography and investigator assessment.
Ahn et al. (2012): Topical application of recombinant IGF-1 to shaved dorsal skin of C57BL/6 mice in telogen. Daily application for 14 days. Hair growth assessed by photography, skin biopsy, and immunohistochemistry for proliferation markers and apoptosis indicators.
Liu et al. (2006): Conditional IGF-1R knockout in mouse follicular keratinocytes using Cre-lox system. Hair cycle analysis by skin color staging, histological sectioning, and electron microscopy of shaft structure.
No human clinical trial protocol for exogenous IGF-1 in hair loss has ever been published or registered.
Dosing in Published Research
The following table summarizes dosing protocols for IGF-1 (Hair-Focused) as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
WHY NO DOSING CHART?
No published dose-response study exists for IGF-1 (Hair-Focused). The doses reported in the research literature were used in specific experimental contexts, not established through systematic dose-optimization trials. Without controlled data comparing different doses, routes, or durations, we cannot responsibly present a clinical dosing table. What the published studies used is described in the text below.
Pharmaceutical Dosing (Mecasermin — Not for Hair)
The only established IGF-1 dosing in humans is for severe primary IGF-1 deficiency in pediatric patients:
| Parameter | Detail |
|---|---|
| Route | Subcutaneous injection |
| Starting dose | 0.04–0.08 mg/kg twice daily |
| Maximum dose | 0.12 mg/kg twice daily |
| Administration | Within 20 minutes of a meal (hypoglycemia risk) |
| Duration | Ongoing—chronic replacement therapy |
| Monitoring | Blood glucose, IGF-1 levels, growth parameters |
This dosing is for growth deficiency treatment and is NOT transferable to hair loss applications. No hair-specific dosing has ever been studied in humans.
Animal Dosing (Ahn et al., 2012)
Topical recombinant IGF-1 applied to mouse dorsal skin. Specific concentrations were not standardized to human scalp application. Results are not translatable to human dosing.
Dosing — Community Protocols
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
IGF-1 (Hair-Focused) has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
WHY NEARLY EMPTY
IGF-1 is not widely used for hair growth in the biohacker or peptide community. The overwhelming majority of community IGF-1 use is for performance enhancement (Cluster N), using IGF-1 LR3 or IGF-1 DES via subcutaneous or intramuscular injection at doses of 20–100 mcg/day.
The few "IGF-1 scalp serum" products that exist do not disclose concentrations in standardized units, making meaningful dosing guidance impossible. Some microneedling practitioners add IGF-1 to their serum cocktails alongside PRP, exosomes, or other growth factors—but this is anecdotal, uncontrolled, and without published protocols or outcomes.
Peptidings does not provide community dosing guidance for IGF-1 in hair applications because no established community protocol exists, and the compound's systemic safety profile—particularly its mitogenic activity and cancer associations—makes self-experimentation with an untested route a risk that exceeds what we are comfortable endorsing.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into IGF-1 (Hair-Focused) combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining IGF-1 (Hair-Focused) with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Frequently Asked Questions
If IGF-1 is so important for hair growth, why hasn't anyone tested it?
Three practical barriers. First, cancer risk—IGF-1 is a potent growth signal for all cells, not just hair cells, and higher blood levels are associated with increased cancer incidence. Any clinical trial would need extensive safety monitoring. Second, delivery—IGF-1 is a 7,649 Da protein that does not passively cross the skin barrier, making topical scalp application pharmacologically challenging. Third, economics—IGF-1 is not patentable, so no company has commercial incentive to fund an expensive clinical trial for a cosmetic indication.
Does finasteride work by increasing IGF-1?
Partially, based on one small study. Inui et al. (2003) found that finasteride responders showed increased IGF-1 mRNA in their dermal papilla cells, while non-responders did not. This suggests that restoring IGF-1 signaling is part of finasteride's mechanism—but finasteride also reduces DHT's other effects on the follicle (miniaturization, sebaceous gland activity), so IGF-1 restoration is not the whole story.
Could taking growth hormone or MK-677 improve my hair by raising IGF-1?
It is biologically plausible—GH secretagogues raise systemic IGF-1, and higher IGF-1 could reach the follicle. But no study has measured hair outcomes from GH or MK-677 use. Systemic IGF-1 elevation also carries the full spectrum of systemic risks (cancer association, metabolic effects), which makes this a disproportionate intervention for hair loss.
Are IGF-1 scalp serums effective?
Unknown. No published study has tested a topical IGF-1 product for hair growth in humans. The fundamental pharmacological question—can a 7,649 Da protein penetrate the scalp in sufficient quantity to reach dermal papilla cells—has not been answered. Products exist; evidence for them does not.
Is IGF-1 the same as IGF-1 LR3 or IGF-1 DES?
No. IGF-1 LR3 is a synthetic analog with an extra 13 amino acids at the N-terminus—it has reduced binding to IGF binding proteins, so it stays active longer. IGF-1 DES is truncated (missing the first 3 amino acids) with increased receptor potency. Both are used for performance enhancement (Cluster N) and have never been studied for hair. They are more potent systemically, which means potentially greater efficacy but also greater safety risk.
If PRP works for hair loss and contains IGF-1, does that prove IGF-1 works?
No. PRP contains IGF-1 among dozens of other growth factors (PDGF, VEGF, TGF-beta, FGF). The contribution of each individual growth factor to PRP's observed effects has never been isolated. Attributing PRP's efficacy to IGF-1 specifically would be the same attribution error seen with Procapil and biotinoyl tripeptide-1.
Could microneedling with IGF-1 be the solution?
It is a plausible hypothesis—microneedling creates microchannels that could improve delivery of the large protein to the follicular unit. But this combination has never been studied. Microneedling also increases systemic absorption unpredictably, which is relevant given IGF-1's mitogenic activity. No protocol, no safety data, no outcomes data.
Does low IGF-1 blood levels mean my hair loss is caused by IGF-1 deficiency?
Not necessarily. Androgenetic alopecia is driven primarily by DHT-mediated follicular miniaturization, which reduces local IGF-1 production as a downstream effect. Low serum IGF-1 may contribute to treatment resistance (Trüeb, 2017), but most AGA patients have normal systemic IGF-1 levels. The deficit is local, in the dermal papilla cells of balding follicles.
Is topical IGF-1 safe?
Unknown. No safety data exists for topical scalp application. The protein's size (7,649 Da) suggests minimal systemic absorption through intact skin, which would limit systemic risk. But this assumption is untested, and microneedling protocols would alter the absorption profile in unpredictable ways.
How does IGF-1 compare to GHK-Cu for hair?
GHK-Cu is a tripeptide (340 Da) with good topical penetration and a broader evidence base for hair—including combination product clinical data. IGF-1 has a stronger mechanistic case specifically for the DPC-keratinocyte growth axis, but it is 22 times larger and has no human hair data. For practical use, GHK-Cu is further along in clinical translation despite weaker mechanism of action evidence.
Could gene therapy targeting IGF-1 in follicles work?
This is an active area of preclinical research. Localized gene therapy to upregulate IGF-1 expression specifically in dermal papilla cells would bypass the delivery problem and the systemic safety concern. But this technology is years from clinical application, and hair loss is unlikely to be the first indication pursued.
What is the connection between aging, IGF-1, and hair loss?
Circulating IGF-1 declines with age, paralleling age-related hair thinning. DPC IGF-1 production also decreases. However, this correlation does not establish causation—aging involves dozens of hormonal, inflammatory, and stem cell changes that independently affect hair. The IGF-1 decline is one thread in a much larger tapestry.
Summary of Key Findings
IGF-1 occupies a unique and paradoxical position in hair biology: no other compound in Cluster K has a stronger mechanistic case for hair growth, and no other has so completely failed to produce clinical evidence for that specific application.
The biology is established beyond reasonable dispute. IGF-1 is the primary mitogenic signal that dermal papilla cells send to follicular keratinocytes. It drives anagen entry, sustains the growth phase, prevents premature apoptosis, and controls hair shaft differentiation. Knockout models confirm it is required. Balding follicles are deficient in it. Finasteride responders restore it.
The translation gap is structural, not scientific. A 7,649 Da protein does not easily penetrate the scalp. Systemic IGF-1 carries cancer risk. There is no commercial incentive to fund a clinical trial for a non-patentable growth factor in a cosmetic indication. These are not problems that enthusiasm or better marketing can solve—they are pharmacological and economic realities.
Verdict Recapitulation
Verdict: Eyes Open. The mechanistic case is among the strongest in this cluster. The clinical evidence for hair specifically is among the weakest. The safety profile of systemic IGF-1 is concerning for a cosmetic indication. Readers should understand IGF-1's established biology—it explains why existing treatments like finasteride work—without interpreting that biology as evidence that exogenous IGF-1 products regrow hair.
For readers considering IGF-1 (Hair-Focused), the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source IGF-1 (Hair-Focused)
Where to Source IGF-1 and Hair Loss
Every partner listed below has been independently reviewed by Peptidings for product quality, third-party testing, and reputation within the research community. We only recommend sources we’d use ourselves.
A telehealth platform founded by board-certified dermatologists specializing in hair loss. Offers custom-compounded topical and oral treatments including finasteride, dutasteride, and minoxidil combinations — prescribed and personalized by physicians, delivered to your door.
View Treatment Options → ↗Further Reading and Resources
If you want to go deeper on IGF-1 (Hair-Focused), the evidence landscape for hair & follicle peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Hair & Follicle Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: IGF-1 (Hair-Focused) — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Trüeb RM. Further clinical evidence for the effect of IGF-1 on hair growth and alopecia. Skin Appendage Disord. 2018;4(2):90-95. PMID 29765966
- Inui S, Fukuzato Y, Nakajima T, Yoshikawa K, Itami S. Androgen-inducible TGF-beta1 from balding dermal papilla cells inhibits epithelial cell growth: a clue to understand paradoxical effects of androgen on human hair growth. FASEB J. 2003;17(13):1895-1897. PMID 12894070
- Ahn SY, Pi LQ, Hwang ST, Lee WS. Effect of IGF-I on hair growth is related to the anti-apoptotic effect of IGF-I and up-regulation of PDGF-A and PDGF-B. Ann Dermatol. 2012;24(1):26-31. PMID: PMC3283847
- Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I and type 1 IGF receptor. Cell. 1993;75(1):59-72. PMID 16778791
- Panchaprateep R, Asawanonda P. Insulin-like growth factor-1: roles in androgenetic alopecia. Exp Dermatol. 2014;23(3):216-218. PMID 24499417
- Sadagurski M, Bhatt RR, White MF. IGF-1 in hair biology. J Invest Dermatol. 2025. PMID 41020895
- Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab. 2004;89(3):1031-1044
DISCLAIMER
IGF-1 (Hair-Focused) is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.